Aigen Investment Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Aigen Investment Management’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-17,773	Closed	-$568K	–	819
2022 Q2	$568K	Buy	+17,773	New	+$520K	0.1%	280
2021 Q3	–	Sell	-11,432	Closed	-$400K	–	714
2021 Q2	$400K	Buy	+11,432	New	+$446K	0.07%	269
2021 Q1	–	Sell	-16,796	Closed	-$727K	–	962
2020 Q4	$727K	Buy	+16,796	New	+$828K	0.09%	284
2020 Q1	–	Sell	-164	Closed	-$13K	–	1663
2019 Q4	$13K	Buy	+164	New	+$9.72K	﹤0.01%	954

Other funds holding GBT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Aigen Investment Management's GBT Position: Q3 2022 in Review

Aigen Investment Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q3 2022, closing a stake of 17,773 shares — an estimated $568K sold.

Aigen Investment Management first reported a position in GBT in Q4 2019 and held it in 4 quarters. The position peaked at $727K in Q4 2020. 247 funds tracked by Wall St. Rank hold GBT as of Q3 2022.

Aigen Investment Management reported no remaining Global Blood Therapeutics, Inc. position as of Q3 2022 after selling out during the quarter.
Aigen Investment Management sold 17,773 Global Blood Therapeutics, Inc. shares in Q3 2022, an estimated $568K.
Aigen Investment Management first reported a position in Global Blood Therapeutics, Inc. in Q4 2019 and held it in 4 quarters.
Aigen Investment Management's Global Blood Therapeutics, Inc. position peaked at $727K in Q4 2020.
247 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2022.

Based on Aigen Investment Management's 13F filing for Q3 2022, filed 9 Nov 2022.